Fusion Antibodies Past Earnings Performance

Past criteria checks 0/6

Fusion Antibodies's earnings have been declining at an average annual rate of -14%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 16.6% per year.

Key information

-14.0%

Earnings growth rate

0.2%

EPS growth rate

Life Sciences Industry Growth36.9%
Revenue growth rate-16.6%
Return on equity-153.6%
Net Margin-88.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Aug 31
Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

Jan 25
Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

May 09
We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%

Mar 17
Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%

Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

Jan 04
Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

Revenue & Expenses Breakdown

How Fusion Antibodies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:FAB Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242-220
30 Jun 241-220
31 Mar 241-220
31 Dec 231-320
30 Sep 232-330
30 Jun 232-330
31 Mar 233-330
31 Dec 224-230
30 Sep 224-230
30 Jun 225-130
31 Mar 225-130
31 Dec 215-230
30 Sep 215-330
30 Jun 214-330
31 Mar 214-330
31 Dec 204-220
30 Sep 204-120
30 Jun 204-120
31 Mar 204-120
31 Dec 194-120
30 Sep 193-120
30 Jun 193-120
31 Mar 192-120
31 Dec 182-120
30 Sep 182-120
30 Jun 182-120
31 Mar 183-110
31 Mar 172010
31 Mar 161110
31 Mar 141000

Quality Earnings: FAB is currently unprofitable.

Growing Profit Margin: FAB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FAB is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.

Accelerating Growth: Unable to compare FAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FAB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).


Return on Equity

High ROE: FAB has a negative Return on Equity (-153.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fusion Antibodies plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robin DavisonAllenby Capital Limited